Patients with Auer rods were more likely to have normal cytogenetics and less likely to have complex karyotype, compared with patients without (P = 0Á056; P = 0Á008; Table I ). Cytogenetic abnormalities sufficient for diagnosing AML with MDS-related changes, according to WHO criteria (Vardiman et al., 2009) , were defined as MDS-specific cytogenetic abnormalities and were more common in patients without Auer rods compared to patients with Auer rods (P = 0Á01; Table I ). Cohorts-1 and -2 had similar frequencies of complex and MDS-specific cytogenetic abnormalities which were lower than cohort-3 (Tables S1 and S2). Patients with Auer rods were less often classified as very-high-risk in IPSS-R (Revised International Prognostic Scoring System) compared with patients without (P = 0Á005; Table I ). This difference was found mainly in cohort-1 (P < 0Á001; Table S1 ), reflecting the lower blast percentage and more favourable cytogenetics of this cohort.
NGS of 112 genes was done on BM samples obtained at diagnosis from 124 patients (Table S3) , including 39 patients with Auer rods, and 85 without Auer rods and detected 202 high-confidence mutations (Table S4 ). There was no significant difference in numbers of mutations (mean, 1Á82 vs. 1Á54; P = 0Á576). Mutation topography is shown in Fig 1A and Figure S1 . NPM1 was the most frequently mutated gene in patients with Auer rods [21%, 95% confidence interval (CI), 9, 36%] followed by DNMT3A (18% [8, 34%]), NRAS (15% [6, 31%]), TET2 (13% [4, 27%]), U2AF1 (13% [4, 27%]), WT1 (10% [3, 24%]) and IDH1 (10% [3, 24%]). In patients without Auer rods, the three most frequently mutated genes were U2AF1 (21% [12, 30%]), TP53 (17% [8, 25%]) and SF3B1 (11%, [4, 17%] ). NPM1, WT1 and IDH1 were significantly more frequently mutated in Auer rod-positive compared with Auer rod-negative patients (P < 0Á001; P = 0Á034; P = 0Á077). No patient with Auer rods had a TP53 mutation, compared with 17% of patients without Auer rods (P = 0Á003).
Previous data indicate that recurrently mutated genes in high-risk MDS (TP53, etc.) differ from those in de novo AML (FLT3, NPM1, DNMT3A, IDH1, IDH2) (Walter et al., 2013) . Patients with Auer rods were more likely to have these AML mutations compared to those without Auer rods [36% (21, 53%) vs. 12% (5, 19%); P = 0Á003; Fig 1B] . This was especially so for patients in cohort-2 [44% (23, 66%); P = 0Á001; Fig 1C] . Similarly, according to the categorising molecular mutations in MDS and AML as reported by correspondence Munich Leukemia Laboratory (Rose et al., 2015) , the AML mutations (NPM1, CEBPA, FLT3, IDH1, IDH2 and CBFB) showed more frequency in patients with Auer rods (33%), both in cohort-1 (31%) and -2 (35%), than those without (13%; P = 0Á013; Figure S2 ). Lindsley et al. (2015) defined NPM1 mutations, MLL/11q23 rearrangements, and CBF rearrangements as de novo-type alterations for AML, and found that NPM1 and TP53 mutations were mutually exclusive. In our cohort, the NPM1 mutation was significantly associated with Auer rods while the TP53 mutation was inversely associated. These data suggest MDS with Auer rods is biologically the same as de novo AML.
Ninety-five patients receiving hypo-methylating drugs and/ or chemotherapy in our centre (Table S5 ) could be evaluated for response using criteria of the MDS International Working Group (Cheson et al., 2006) . Patients with Auer rods receiving chemotherapy (with or without hypo-methylating drugs) had a higher frequency of complete remission compared to patients received hypo-methylating drugs only [64% (31, 89%) vs. 20% (3, 56%); P = 0Á08; Table S6 ]. Previous studies reported that patients with MDS and Auer rods responded better to intensive AML-like chemotherapy than patients without Auer rods (Seymour & Estey, 1995) . Conversely, we detected no difference in complete response rates with these regimens in patients without Auer rods (25% vs. 23%; P = 0Á835; Table S6 ). There was also no difference in the overall response rate between these cohorts (P > 0Á1, Table S6 ).
In patients with Auer rods, those receiving chemotherapy (with or without hypo-methylating drugs) had a longer median survival compared to those patients with Auer rods receiving only hypo-methylating drugs (53 vs. 15 months; P = 0Á041; Fig 1D) . This difference was not detected in patients without Auer rods (18 vs. 21 months; P = 0Á642; Figure S3A ). Amongst patients receiving chemotherapy (with or without hypo-methylating drugs), those with Auer rods Figure S3B ). MDS was previously called preleukemia, smoldering leukemia, or oligoblastic leukemia (Heaney & Golde, 1999) . Albitar et al. (2002) reported MDS as biologically and clinically distinct from AML. Others think some cases are similar (Gale & Bennett, 2009 ). In the past decade, distinction of the mutation spectrum between MDS and AML (as discovered by NGS) indicate that MDS is distinct from AML in many respects, just as splicing gene mutations are more common in people with MDS, and transcription gene abnormalities are more common in people with AML (Walter et al., 2013) .
Our data indicate that patients with MDS and Auer rods have a high frequency of AML-related mutations. We suggest that MDS with Auer rods is a special subgroup which is biologically more akin to AML, regardless of blasts percentage, and may benefit from chemotherapy. Because our study was retrospective, our conclusions require validation. 
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